Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon Launches LNA™ Gapmers

Published: Wednesday, March 20, 2013
Last Updated: Wednesday, March 20, 2013
Bookmark and Share
Inhibition of mRNA and lncRNA in functional studies.

Exiqon A/S has announced the launch of its LNA™ longRNA GapmeR products for specific and efficient inhibition of mRNA and lncRNA.

The LNA™ longRNA GapmeRs are high affinity antisense oligonucleotides used for functional analysis, allowing researches to study the gene function and downstream biological consequences of silencing a specific mRNA or long non-coding RNA (lncRNA) in cell-cultures or animal models.

The broad range of LNA™ longRNA GapmeR products enables researcher to start from initial cost-effective in vitro screening in cell-lines of multiple gapmer designs and continue with high-purity animal-grade gapmers for in vivo testing.

The use of LNA™ enhanced antisense oligonucleotides in functional studies ensures superior performance and higher success rate through increased target accessibility, specificity, binding affinity, and tolerance.

In addition, the LNA™ longRNA GapmeRs enable easy unassisted (gymnotic) delivery into the cells resulting in broader applicability including hard-to-transfect cells lines.

By use of single-stranded RNase H-activating gapmer designs even targets in the nucleus can be addressed which may not be possible with alternative methods.

“We are thrilled to offer the LNA™ longRNA GapmeR products to our customers. The product line has already been tested by certain early access customer who clearly demonstrated the scientific potential of this product offering.” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller.

All the LNA™ longRNA GapmerR are designed using Exiqon’s advanced and proprietary bioinformatics design algorithm which in combination with the LNA™ technology secure gapmers with excellent pharmacokinetic and pharmacodynamics properties including high stability and low toxicity for in vivo testing.

The incorporation of LNA™ increases the bio-stability which secures the biological activity over an extended period of time.

Exiqon offers a range of compatible LNA™ enhanced products for mRNA and lncRNA research including products for qPCR and in situ hybridization analysis.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Mystery of the Instant Noodle Chromosomes
Researchers from the Lomonosov Moscow State University evaluated the benefits of placing the DNA on the principle of spaghetti.
Oxitec ‘Self-Limiting Gene’ Offers Hope for Controlling Invasive Moth
A new pesticide-free and environmentally-friendly way to control insect pests has moved ahead with the publication of results showing that Oxitec diamondback moths (DBM) with a ‘self-limiting gene’ can dramatically reduce populations of DBM.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
Kiwi Bird Genome Sequenced
The kiwi, national symbol of New Zealand, gives insights into the evolution of nocturnal animals.
Scientists Identify Schizophrenia’s “Rosetta Stone” Gene
Scientists have identified a critical function of what they believe to be schizophrenia’s “Rosetta Stone” gene that could hold the key to decoding the function of all genes involved in the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!